Co-morbidity, outcome, all-cause survival, biochemical recurrence, and additional treatment

So we have all heard the commonly used phrase that men with diagnosed with prostate cancer are “more likely to die with prostate cancer than of it” — and there is certainly truth to this generalization. … READ MORE …

Is standardization of the PSA cutpoint for biochemical recurrence after surgery a good idea?

A paper just published in this month’s issue of the Journal of Urology has suggested that the true cutpoint for PSA levels indicative of biochemical recurrence in the highest number of patients is actually 0.4 ng/ml (as opposed to the oft-stated 0.2 ng/ml). … READ MORE …

New fluorine-18-based imaging agent approved in USA

Last Friday the US Food and Drug Administration (FDA) last Friday approved a new type of imaging agent for use in PET/CT scans for men with suspected prostate cancer recurrence after earlier treatment. … READ MORE …

ED drugs and risk for prostate cancer recurrence? … NOT!

Back in February 2015 a group of German researchers published a study suggesting that there was a small but significantly increased risk of biochemical recurrence after prostate cancer treatment among men using drugs like sildenafil (Viagra) to recover/stimulate erectile function. … READ MORE …

Site of cancer recurrence after first-line (primary) radiation therapy

This is the first part of a two-part commentary. In this part we look at studies that identified the site of failure after primary radiation treatment. In the second part we will look at how stereotactic body radiation therapy (SBRT) is being used to treat such local recurrences. … READ MORE …

Can a daily aspirin prevent recurrence of early stage prostate cancer after first-line treatment?

According to media reports on the BBC’s web site and in The Guardian newspaper in the UK, a new clinical trial to be implemented by the National Health Service (NHS) will explore whether a simple aspirin regimen can be used to help to prevent the recurrence of certain types of early stage cancer following first-line treatment. … READ MORE …

Not all men with Gleason 8-10 disease are going to do badly after treatment

There is a perception among a lot of patients — especially when they get diagnosed — that having a high Gleason score of 8, 9, or 10 is essentially a “death sentence”, regardless of how they get treated. … READ MORE …

Johns Hopkins: ultrasensitive PSA after surgery predicts biochemical relapse

We’ve looked at several retrospective studies this year that found that early ultrasensitive PSA (uPSA) results following surgery can reliably predict eventual biochemical relapse. Johns Hopkins examined its own database and found the same thing. … READ MORE …

If you have positive surgical margins post-surgery, you need to …

… know the Gleason score of the tissue at that positive surgical margin as well as and as opposed to just the Gleason score of the primary tumor. It makes a difference to your risk for biochemical recurrence. Your doctors need to know this information too! … READ MORE …

What … you’re afraid your cancer might recur? What a surprise!

There is some scientific literature that gets presented and published that makes one wonder, seriously, what is going on in the minds of the researchers — let alone in the minds of the people who agree to fund such research. … READ MORE …

Biochemical recurrence among pT2 patients with a positive surgical margin post-surgery

A new paper by a group of German researchers and clinicians has provided us with expanded insight into risk for biochemical recurrence for men with organ-confined prostate cancer and a positive surgical margin based on their post-surgical pathology report. … READ MORE …

Smoking isn’t good for men with prostate cancer (redux)

Back in 2011 we commented on a report indicating that men who continued smoking after initial treatment for prostate cancer (or who were smokers up to 10 years prior to their treatment) were at significantly higher risk for prostate cancer progression than non-smokers. … READ MORE …

Does use of PDE5 inhibitors post-treatment affect risk for biochemical recurrence?

A new article in the February 2015 of the Journal of Urology may actually tell us as much (or more) about the difficulties of relying on data from large, retrospective analyses of single institution data as it does about the actual issue references in the headline above. … READ MORE …

Low detectable PSA after prostatectomy – watch or treat?

In a previous article, we looked at evidence that a low detectable level of PSA predicts eventual biochemical recurrence (a confirmed PSA greater than 0.2 ng/ml) when there is aggressive pathology. … READ MORE …

The dangers of using nomograms to compare apples to oranges

A cross-specialty group of prostate cancer experts has reviewed data from > 13,000 patients on the accuracy of nomograms in predicting biochemical recurrence and actual prostate cancer-specific mortality after three different types of treatment. … READ MORE …